Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Reduced by Tobam

Tobam lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 36.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 597 shares of the biopharmaceutical company’s stock after selling 347 shares during the quarter. Tobam’s holdings in Regeneron Pharmaceuticals were worth $425,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of REGN. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Regeneron Pharmaceuticals by 3.4% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,872 shares of the biopharmaceutical company’s stock worth $14,155,000 after buying an additional 652 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after acquiring an additional 1,108 shares in the last quarter. Ledyard National Bank raised its position in shares of Regeneron Pharmaceuticals by 2.1% during the 4th quarter. Ledyard National Bank now owns 6,525 shares of the biopharmaceutical company’s stock valued at $4,648,000 after acquiring an additional 134 shares in the last quarter. Financial Advocates Investment Management bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth $474,000. Finally, Private Wealth Management Group LLC boosted its holdings in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 39 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.7 %

Shares of Regeneron Pharmaceuticals stock opened at $722.07 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a market cap of $79.35 billion, a P/E ratio of 17.87, a P/E/G ratio of 1.60 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average price of $717.27 and a 200 day moving average price of $914.93.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the business posted $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.49%. The ex-dividend date is Thursday, February 20th.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on REGN. Sanford C. Bernstein decreased their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Barclays decreased their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target on the stock. Robert W. Baird reduced their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the company from $762.00 to $834.00 in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.